Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report

Abstract Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset of non‐small cell lung cancer (NSCLC). The rapid progression of ALK inhibitors has significantly prolonged the progression‐free survival of patients with ALK gene‐sensitive mutations. However, the response of patients w...

Full description

Bibliographic Details
Main Authors: Kunyan Sun, Ligong Nie, Lin Nong, Yuan Cheng
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:Thoracic Cancer
Subjects:
alectinib
ALK rearrangement
crizotinib
non‐small cell lung cancer
STRN‐ALK
Online Access:https://doi.org/10.1111/1759-7714.13983

Similar Items

Similar Items